Literature DB >> 7729733

UCI-VULV-1, a vulvar squamous carcinoma cell line.

P M Carpenter1, G Gamboa-Vujicic, J T Mascarello, S Wilczynski, M Bhaumik, G Dorion, A Manetta.   

Abstract

Squamous carcinoma of the vulva (SCV) is an uncommon neoplasm of uncertain etiology. There is evidence that there are two subgroups of SCV, one associated with human papilloma virus (HPV) and a second HPV-negative group. The UCI-VULV-1 cell line, obtained from a lymph node metastasis of an SCV, grows with a population doubling time of approximately 60 hr. The saturation density is 10(5) cells/cm2. The cell line does not exhibit anchorage independence and is weakly tumorigenic. The cells range in appearance from an abundant spindle cell to a less common larger, flat cell. All of the cells are immunoreactive for high-molecular-weight keratin, but only the flat cells, which form squamous pearls in vivo, are immunoreactive for low-molecular-weight keratin. The cell line expresses epidermal growth factor (EGF), transforming growth factor-alpha, the EGF receptor, and p53 protein. Polymerase chain reaction revealed no HPV DNA within the cells. Early passage cells exhibited karyotypic heterogeneity with few similarities to previous described SCV karyotypes. The cells display sensitivity to cis-platinum in concentrations toxic to many ovarian and cervical carcinoma lines. UCI-VULV-1 may be helpful for studying the properties of the HPV-negative form of SCV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729733     DOI: 10.1006/gyno.1995.1124

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  1 in total

1.  Establishment and characterization of two squamous cell carcinoma cell lines (HYVC and HMVC) derived from vulva.

Authors:  Kazushige Kiguchi; Isamu Ishiwata; Chieko Ishiwata; Masanori Iwata; Bunpei Ishizuka; Hiroyuki Yoshikawa; Toshiaki Tachibana; Hisashi Hashimoto; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2002-12       Impact factor: 4.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.